Publication & Citation Trends
Publications
0 total
Abstract 5864: Taletrectinib, a next generation selective ROS1 inhibitor, demonstrates a differentiated profile in ROS1 fusion models
Cited by 0
Semantic Scholar
Challenging paradigms: utilizing pancreatic cancer organoids to advance personalized medicine
Cited by 0
Semantic Scholar
P3.12.04 Taletrectinib, a Next Generation Selective ROS1 Inhibitor, Exhibits a Differentiated Profile in ROS1 Fusion Models
Cited by 0
Semantic Scholar
Abstract 5612: Taletrectinib, a next generation selective ROS1 inhibitor, inhibits growth of ROS1 wild-type and ROS1-G2032R xenografts
Cited by 0
Semantic Scholar
Abstract 6264: NUV-868, a novel BD2-selective BET inhibitor, in combination with enzalutamide or olaparib, inhibits growth of solid tumor xenografts
Cited by 3
Semantic Scholar
Abstract CT073: Efficacy of novel oral SERD elacestrant in fulvestrant-refractory hormone receptor-positive (HR+) breast cancer: a translational investigation
Cited by 0
Semantic Scholar
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells OA
Cited by 4
Semantic Scholar
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer OA
Cited by 13
Semantic Scholar
Research Topics
Estrogen and related hormone effects
(45)
Advanced Breast Cancer Therapies
(18)
HER2/EGFR in Cancer Research
(9)
Prostate Cancer Treatment and Research
(7)
Breast Cancer Treatment Studies
(5)
Affiliations
University of Illinois Urbana-Champaign
Illinois College
University of Illinois Chicago
Radius Health (United States)
Nuvotronics (United States)